Safety of adeno-associated viral vectors

Future Virology

Volumn 3, Issue 5, 2008, Pages 491-503

  Lin, Shih Wen ^a,b   Ertl, Hildegund C J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

Adeno assoclated viral vectors; Adeno assoclated virus; Clinical trials; Gene therapy; Vaccine carriers

Indexed keywords

BETA GLUCURONIDASE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYCLOSPORIN; DOUBLE STRANDED DNA; DYSTROPHIN; ERYTHROPOIETIN; ETANERCEPT; EYE PROTEIN; GAG PROTEIN; GENE PRODUCT; GLUTAMATE DECARBOXYLASE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MEROZOITE SURFACE PROTEIN 4; MEROZOITE SURFACE PROTEIN 5; MICRORNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARASITE ANTIGEN; PROTEIN RPE 65; REP78 PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY RESPONSE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BLEEDING; CANAVAN DISEASE; CANCER GENE THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG SAFETY; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; EPILEPSY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INSERTION; GENE REPLACEMENT THERAPY; GENE TRANSFER; HEMOPHILIA A; HISTOPLASMOSIS; HUMAN; INFECTION; MALIGNANT NEOPLASTIC DISEASE; MUCOPOLYSACCHARIDOSIS TYPE 7; MULTIPLE ORGAN FAILURE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS RECOMBINANT;

ADENO-ASSOCIATED VIRUS; ANIMALIA;

EID: 55849127475     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.3.5.491     Document Type: Review

References (135)

1. Chu Q, Moreland R, Yew NS, Foley J, Ziegler R, Scheule RK: Systemic insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy. Mol. Ther. (2008).
2. Lu H, Chen L, Wang J et al.: Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. Hum. Gene Ther. 19(6), 648-654 (2008).
3. Coura Rdos S, Nardi NB: The state of the art of adeno-associated virus-based vectors in gene therapy. Virol. 14, 99 (2007).
4. Wang CH, Liu DW, Tsao YP, Xiao X, Chen SL: Can genes transduced by adeno-associated virus vectors elicit or evade an immune response? Arch. Virol. 149, 1-15 (2004).
5. Zaiss AK, Muruve DA: Immune responses to adeno-associated virus vectors. Curr. Gene Ther. 5, 323-331 (2005).
6. Manning WC, Paliard X, Zhou S et al.: Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J. Virol. 71, 7960-7962 (1997).
7. Xin KQ, Urabe M, Yang J et al.: A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum. Gene Ther. 12, 1047-1061 (2001).
8. Du L, He Y, Wang Y et al.: Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: implication for developing SARS vaccines. Virology 353, 6-16 (2006).
9. Xie LH, Sin FW, Cheng SC et al.: Activation of cytotoxic T lymphocytes against CML28-bearing tumors by dendritic cells transduced with a recombinant adeno-associated virus encoding the CML28 gene. Cancer Immunol. Immunother. 57(7), 1029-1038 (2008).
10. You H, Liu Y, Prasad CK et al.: Multiple human papillomavirus genes affect the adeno-associated virus life cycle. Virology 344, 532-540 (2006).
11. Casto BC, Atchison RW, Hammon WM: Studies on the relationship between adeno-associated virus type-1 (AAV-1) and adenoviruses: I. Replication of AAV-1 in certain cell cultures and its effect on helper adenovirus. Virology 32, 52-59 (1967).
12. Buller RML, Janik JE, Sebring ED, Rose JA: Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J. Virol. 40, 241-247 (1981).
13. Blacklow NR, Hoggan MD, Rowe WP: Serologic evidence for human infection with adenovirus-associated viruses. J. Natl Cancer Inst. 40, 319-327 (1968).
14. Berns KI, Giraud C: Biology of adeno-associated virus. Curr. Top. Microbiol. Immunol. 218, 1-23 (1996).
15. Goncalves MA: Adeno-associated virus: from defective virus to effective vector. Virol. J. 2, 43 (2005).
16. Smith-Arica JR, Bartlett JS: Gene therapy: recombinant adeno-associated virus vectors. Curr. Cardiol. Rep. 3, 43-49 (2001).
17. Ni T-H, McDonald WF, Zolotukhin I et al.: Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. J. Virol. 72, 2777-2787 (1998).
18. Gao GP, Lu F, Sanmiguel JC et al.: Repl Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Repl Cap. Mol. Ther. 5, 644-649 (2002).
19. Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR: Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol. Ther. 2, 394-403 (2000).
20. Linden RM, Berns KI: Molecular biology of adeno-associated viruses. Contrib. Microbiol. 4, 68-84 (2000).
21. Timpe J, Bevington J, Casper J, Dignam JD, Trempe JP: Mechanisms of adeno-associated virus genome encapsidation. Curr. Gene Ther. 5, 273-284 (2005).
22. Blackdow NR: Paroviruses and Human Disease. Pattison JR (Ed.). Clinical Research Collaboration, Boca Raton, FL, USA, 117-132 (1988).
23. Duan D, Sharma P, Yang J et al..: Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 72, 8568-8577 (1998).
24. Weitzman MD, Kyostio SR, Kotin RM, Owens RA: Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc. Natl Acad. Sci. USA 91, 5808-5812 (1994).
25. Young SM Jr, McCarty DM, Degtyareva N, Samulski RJ: Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombinatton. J. Virol. 74, 3953-3966 (2000).
26. Wonderling RS, Owens RA: Binding sites for adeno-associated virus Rep proteins within the human genome. J. Virol. 71, 2528-2534 (1997).
27. McAlister VJ, Owens RA: Preferential integration of adeno-associated virus type 2 into a polypyrimidine/polypurine-rich region within AAVS1. J. Virol. 81. 9718-9726 (2007).
28. Lamartina S, Sporeno E, Fattori E, Toniatti C: Characteristics of the adeno-associated virus preintegration site in human chromosome 19: open chromatin conformation and transcription-competent environment. J. Virol. 74, 7671-7677 (2000).
29. Huser D, Weger S, Heilbronn R: Packaging of human chromosome 19-specific adeno-associated virus (MV) integration sites in AAV virions during AAV wild-type and recombinant AAV vector production. J. Virol. 77, 4881-4887 (2003).
30. Donsante A, Miller DG, Li Y et al.: AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477 (2007).
31. Donsante A, Vogler C, Muzyczka N et al.: Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 8, 1343-1346 (2001).
32. Nakai H, Montini E, Fuess S, Storm TA, Grompe M, Kay MA: AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet. 34, 297-302 (2003).
33. Berns KI: Parvovirus replication. Microbiol. Mol. Biol. Rev. 54, 316-329 (1990).
34. Kenneth I, Berns RML: The cryptic life style of adenoassociated virus. BioEssays 17, 237-245 (1995).
35. Muzyczka N, Samulski RJ, Hermonat P, Srivastava A, Berns KI: The genetics of adeno-associated virus. Adv. Exp. Med. Biol. 179, 151-161 (1984).
36. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl Acad. Sci. USA 99, 11854-11859 (2002).
37. Gao G, Vandenberghe LH, Alvira MR et al.: Glades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-6388 (2004).
38. Samulski RJ, Berns KI, Tan M, Muzyczka N: Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human calls. Proc. Natl Acad. Sci. USA 79, 2077-2081 (1982).
39. Hermonat PL, Muzyczka N: Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl Acad. Sci. USA 81, 6466-6470 (1984).
40. Summerford C, Bartlett JS, Samuiski RJ: αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5, 78-82 (1999).
41. Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ: Adeno-associated virus type 2 contains an integrin α5β1 binding domain essential for viral cell entry. J. Virol. 80, 8961-8969 (2006).
42. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA: The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80, 9831-9836 (2006).
43. Kurzeder C, Koppold B, Sauer G, Pabst S, Kreienberg R, Deissler H: CD9 promotes adeno-associated virus type 2 infection of mammary carcinoma cells with low cell surface expression of heparan sulphate proteoglycans. Int. J. Mol. Med. 19, 325-333 (2007).
44. Schultz BR, Chamberlain JS: Recombinant adeno-associated virus transduction and integration. Mol. Ther. 16(7), 1189-1199 (2008).
45. Lochrie M, Tatsuno G, Arbetman A et al.: Characterization of a murine adeno-associated virus (AAV-mo. 1) capsid. Mol. Ther.: 11, S52-S53 (2005).
46. Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ: Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80. 11393-11397 (2006).
47. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A: Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5, 71-77 (1999).
48. Douar AM, Poulard K, Stockholm D, Danos O: Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J. Virol. 75, 1824-1833 (2001).
49. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T. Engelhardt JF: Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J. Virol. 74, 9184-9196 (2000).
50. Bartlett JS, Wilcher R, Samulski RJ: Infectious entry pathway of adeno-associated virus and, adeno-asaociated virus vectors. J. Virol. 74, 2777-2785 (2000).
51. Gao G, Vandenberghe LH, Wilson JM: New recombinant serotypes of AAV vectors. Curr. Gene Ther.: 5, 285-297 (2005).
52. Louboutin JP, Wang L, Wilson JM: Gene transfer into skeletal muscle using novel AAV serotypes. J. Gene Med. 7, 442-451 (2005).
53. Taymans JM, Vandenberghe LH, Haute CV et al.: Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum. Gene Ther. 18, 195-206 (2007).
54. Thorsen F, Afione S, Huszthy PC et al.: Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. J. Gene Med. 8, 1131-1140 (2006).
55. Cearley CN, Wolfe JH: Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther. 13. 528-537 (2006).
56. Wright JF, Qu G, Tang C, Sommer JM: Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr Opin. Drug Discov. Devel. 6, 174-178 (2003).
57. Wang H, Lieber A: A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kiobase transgene cassette. J. Virol. 80, 11699-11709 (2006).
58. Geoffroy MC, Salvetti A: Helper functions required for wild type and recombinant adeno-associated virus growth. Curr. Gene Ther. 5, 265-271 (2005).
59. McCarty DM, Fu H, Monahan PE, Toulson CE, Nalk P, Samulski RJ: Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10, 2112-2118 (2003).
60. McCarty DM, Monahan PE, Samulski RJ: Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8, 1248-1254 (2001).
61. Wu J, Zhao W, Zhong L et al.: Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum. Gene Ther. 18(2), 171-182 (2007).
62. Sun L, Li J, Xiao X: Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med. 6, 599-602 (2000).
63. Yan Z, Lei-Butters DC, Zhang Y, Zak R, Engelhardt JF: Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo. Hum. Gene Ther. 18, 81-87 (2007).
64. Yue Y, Duan D: Double strand interaction is the predominant pathway for intermolecular recombination of adeno-associated viral genomes. Virology 313, 1-7 (2003).
65. Li C, Samulski RJ: Serotype-specific replicating AAV helper constructs increase recombinant AAV type 2 vector production. Virology 335, 10-21 (2005).
66. Allocca M, Doria M, Petrillo M et al.: Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J. Clin. Invert. 118, 1955-1964 (2008).
67. Durocher Y, Pham PL, St-Laurent G et al.: Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. J. Virol. Methods 144, 32-40 (2007).
68. Leonard JN, Ferstl P, Delgado A, Schaffer DV: Enhanced preparation of adeno-associated viral vectors by using high hydrostatic pressure to selectively inactivate helper adenovirus. Biotechnol. Bioeng. 97, 1170-1179 (2007).
69. Blouin V, Brument N, Toublanc E, Raimbaud I, Moullier P, Salvetti A: Improving rAAV production and purification: towards the definition of a scaleable process. J. Gene Med. 6(Suppl. 1), S223-S228 (2004).
70. Nony P, Chadeuf G, Tessier J, Moullier P, Salvetti A: Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) TYPE 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles. J. Virol. 77, 776-781 (2003).
71. Chadeuf G, Ciron C, Moullier P, Salvetti A: Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol. Ther. 12, 744-753 (2005).
72. Russell DW, Miller AD, Alexander IE: Adeno-associated virus vectors preferentially transduce cells in S phase. Proc. Natl Acad. Sci. USA 91, 8915-8919 (1994).
73. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM: Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70, 520-532 (1996).
74. Nakai H, Storm TA, Kay MA: Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat. Biotechnol. 18, 527-532 (2000).
75. Miller DG, Petek LM, Russell DW: Adeno-associated virus vectors integrate at chromosome breakage sites. Nat. Genet. 36, 767-773 (2004).
76. Miller DG, Trobridge GD, Petek LM, Jacobs MA, Kaul R, Russell DW: Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J. Virol. 79, 11434-11442 (2005).
77. Inagaki K, Ma C, Storm TA, Kay MA, Nakai H: The role of DNA-PKcs and artemis in opening viral DNA hairpin termini in various tissues in mice. J. Virol. 81, 11304-11321 (2007).
78. Donsante A, Vogler C, Muzyczka N et al.: Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 8, 1343-1346 (2001).
79. Kay MA: AAV vectors and tumorigenicity. Nat. Biotech. 25, 1111-1113 (2007).
80. Bell P, Wang L, Lebherz C et al.: No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol. Ther. 12, 299-306 (2005).
81. Chirmule N, Xiao W, Truneh A et al.: Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J. Virol. 74, 2420-2425 (2000).
82. Xiao W, Chirmule N. Schnell MA, Tazelaar J, Hughes JV, Wilson JM: Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol. Ther. 1, 323-329 (2000).
83. Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR: Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73, 8549-8558 (1999).
84. Manno CS, Chew AJ, Hutchison S et al.: AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972 (2003).
85. McPhee SW, Janson CG, Li C et al.: Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med. 8, 577-588 (2006).
86. Ge Y, Powell S, Van Roey M, McArthur JG: Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 97, 3733-3737 (2001).
87. + T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110, 1132-1140 (2007).
88. Nathwani AC, Davidoff AM, Hanawa H et al.: Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 100, 1662-1669 (2002).
89. Gao G, Lebherz C, Weiner DJ et al.: Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103, 3300-3302 (2004).
90. Chenuaud P, Larcher T, Rabinowitz JE et al.: Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103, 3303-3304 (2004).
91. Han G, Wang R, Chen G et al.: Gene delivery GAD 500 autoantigen by AAV serotype 1 prevented diabetes in mice NOD: transduction efficiency do not play important roles. Immunol. Lett. 115, 110-116 (2008).
92. High K: MV-mediated gene transfer for hemophilia. Genet. Med. 4, 56S-61S (2002).
93. Flotte TR: Adeno-associated virus-based gene therapy for inherited disorders. Pediatr. Res. 58, 1143-1147 (2005).
94. Duan D: From the smallest virus to the biggest gene: marching towards gene therapy for Duchenne muscular dystrophy. Discov. Med. 6, 103-108 (2006).
95. Ponder KP, Haskins ME: Gene therapy for mucopolysaccharidosis. Expert Opin. Biol. Ther. 7, 1333-1345 (2007).
96. Noe F, Nissinen J, Pitkanen A et al.: Gene therapy in epilepsy: the focus on NPY. Peptides 28, 377-383 (2007).
97. Allocca M, Tessitore A, Cotugno G, Auricchio A: AAV-mediated gene transfer for retinal diseases. Expert Opin. Biol. Ther. 6, 1279-1294 (2006).
98. Le Meur G, Stieger K, Smith AJ et al.: Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther. 14, 292-303 (2007).
99. Park K, Kim WJ, Cho YH et al.: Cancer gene therapy using adeno-associated virus vectors. Front. Biosci. 13, 2653-2659 (2008).
100. Williams DA: RAC reviews serious adverse event associated with AAV therapy trial. Mol. Ther. 15, 2053-2054 (2007).
101. Levicoff EA, Kim JS, Sobajima S et al.: Safety assessment of intradiscal gene therapy II: effect of dosing and vector choice. Spine 33, 1509-1516 (2008).
102. Bedrosian JC, Gratton MA, Brigande JV, Tang W, Landau J, Bennett J: In vivo delivery of recombinant viruses to the fetal murine cochlea: transduction characteristics and long-term effects on auditory function. Mol. Ther. 14, 328-335 (2006).
103. Manno CS, Arruda VR, Pierce GF et al.: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347 (2006).
104. Schuettrumpf J, Liu JH, Couto LB et al.: Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial. Mol. Ther. 13, 1064-1073 (2006).
105. Kaplitt MG, Feigin A, Tang C et al.: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson' disease: an open label, Phase I trial. Lancet 369, 2097-2105 (2007).
106. Bennicelli J, Wright JF, Komaromy A et al.: Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol. Ther. 16, 458-465 (2008).
107. Jacobson SG, Boye SL, Aleman TS et al.: Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum. Gene Ther. 17, 845-858 (2006).
108. Jacobson SC, Acland GM, Aguirre GD et al.: Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol. Ther. 13, 1074-1084 (2006).
109. McPhee SW, Janson CG, Li C et al.: Immune responses to AAV in a Phase I study for Canavan disease. J. Gene Med. 8, 577-588 (2006).
110. Yuasa K, Yoshimura M, Urasawa N et al.: Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther. 14, 1249-1260 (2007).
111. + T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419-422 (2007).
112. + T cells are unable to eliminate AAV-transduced hepatocytes. Mol. Ther. 15, 792-800 (2007).
113. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E et al.: Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110, 2334-2341 (2007).
114. Jiang H, Couto LB, Patarroyo-White S et al.: Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108, 3321-3328 (2006).
115. Nathwani AC, Gray JT, McIntosh J et al.: Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109, 1414-1421 (2007).
116. Vandendriessche T, Thorrez L, Acosta-Sanchez A et al.: Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs lentiviral vectors for hemophilia B gene therapy. J. Thromb. Haemost. 5, 16-24 (2007).
117. Monahan PE, Jooss K, Sands MS: Safety of adeno-associated virus gene therapy vectors a current evaluation. Expert Opin. Drug Saf. 1, 79-91 (2002).
118. Logan GJ, Wang L, Zheng M, Cunningham SC, Coppel RL, Alexander IE: AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection. Vaccine 25, 1014-1022 (2007).
119. Wang L, Figueredo J, Calcedo R, Lin J. Wilson JM: Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum. Gene Ther. 18, 185-194 (2007).
120. Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW: Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 105, 4226-4234 (2005).
121. Sarukhan A, Camugli S, Gjata B. von Boehmer H, Danos O, Jooss K: Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J. Virol. 75, 269-277 (2001).
122. Xin KQ, Ooki T, Mizukami H et al.: Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum. Gene Ther. 13. 1571-1581 (2002).
123. Liu DW, Tsao YP, Kung JT et al.: Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol. 74, 2888-2894 (2000).
124. Mahadevan M, Liu Y, You C et al.: Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. Cancer Immunol. Immunother. 56, 1615-1624 (2007).
125. You H, Liu Y, Cong M et al.: HBV genes induce cytotoxic T-lymphocyte response upon adeno-associated virus (AAV) vector delivery into dendritic cells. J. Viral Hepat. 13, 605-612 (2006).
126. Liu Y, Zhou W, You C et al.: An autoimmune domain-reduced HCV core gene remains effective in stimulating anti-core cytotoxic T lymphocyte activity. Vaccine 24, 1615-1624 (2006).
127. Liu Y, Chiriva-Internati M, You C et al.: Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. Cancer Gene Ther. 12, 304-312 (2005).
128. Chiriva-Internati M, Liu V, Salati E et al.: Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J. Immunol. 32, 30-38 (2002).
129. Liu Y, Chiriva-Internati M, Grizzi F et al.: Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther. 8, 948-957 (2001).
130. Johnson PR, Schnepp BC, Connell MJ et al.: Novel adeno-associated virus vector vaccine restricts replication of simian Immunodeficiency virus in macaques. J. Virol. 79, 955-965 (2005).
131. van Lunzen J, Mehendale S, Clumeck N et al..: A Phase I study to evaluate the safety and immunogenicity of a recombinant adeno-associated virus vaccine. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 February 2007.
132. + T cells in mice. J Clin. Invest. 117, 3958-3970 (2007).
133. + T cell responses in mice. J. Virol. 81(21), 11840-11849 (2007).
134. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X: Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 10, 2105-2111 (2003).
135. Fluri DA, Baba MD, Fussenegger M: Adeno-associated viral vectors engineered for macrolide-adjustable transgene expression in mammalian cells and mice. BMC Biotechnol. 7, 75 (2007).